AstraZeneca (AZN) buys the rights to a rheumatoid arthritis drug from Rigel Pharmaceuticals...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (AZN) buys the rights to a rheumatoid arthritis drug from Rigel Pharmaceuticals (RIGL) in a deal potentially worth up to $1.245B. AstraZeneca is betting the drug will succeed in Phase III tests, despite one Phase II failure last July.